AquaBounty Technologies (NASDAQ:AQB) Issues Quarterly Earnings Results

AquaBounty Technologies (NASDAQ:AQB) announced its earnings results on Thursday. The company reported ($0.20) EPS for the quarter, Zacks reports.

AquaBounty Technologies Trading Down 1.1%

NASDAQ:AQB traded down $0.01 during midday trading on Friday, hitting $0.94. 27,721 shares of the stock were exchanged, compared to its average volume of 42,436. AquaBounty Technologies has a one year low of $0.63 and a one year high of $2.95. The company has a market capitalization of $4.84 million, a price-to-earnings ratio of -1.13 and a beta of 1.36. The business has a 50-day moving average price of $0.94 and a two-hundred day moving average price of $0.98.

Institutional Investors Weigh In On AquaBounty Technologies

An institutional investor recently bought a new position in AquaBounty Technologies stock. Two Sigma Investments LP bought a new position in shares of AquaBounty Technologies, Inc. (NASDAQ:AQB) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,565 shares of the company’s stock, valued at approximately $84,000. Two Sigma Investments LP owned approximately 0.97% of AquaBounty Technologies at the end of the most recent reporting period. Institutional investors and hedge funds own 8.92% of the company’s stock.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc is a biotechnology company focused on aquaculture innovation through the development and commercialization of genetically engineered fish. Its flagship product, AquAdvantage Salmon, is an Atlantic salmon strain enhanced with a growth hormone gene that enables faster growth and more efficient feed conversion compared with conventional farmed salmon. By integrating biotechnology into seafood production, AquaBounty aims to address global protein demand while reducing the environmental footprint associated with marine aquaculture.

Founded in 1991, AquaBounty is headquartered in Maynard, Massachusetts, and operates a state-of-the-art, land-based incubation and grow-out facility in Panama.